Aurobindo Upbeat On Outlook, Transfers Biologics Biz
Seeks FDA Desk Reviews For Three Units
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
